Phase III long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertension

Trial Profile

Phase III long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs SJP 0135 (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 15 Mar 2017 New trial record
    • 10 Mar 2017 Status has been changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top